We are proud to announce that Northwest Medical Specialties (NWMS) has enrolled its first patient in a trispecifics study, led by Principal Investigator Dr. Sibel Blau. This milestone follows the launch of our bispecifics program in January 2024 and reflects our continued commitment to bringing cutting-edge treatments to our community.
Currently, NWMS is participating in multiple clinical trials involving bispecific antibodies in the outpatient setting and has now launched its first trispecific antibody trial. Bispecific and trispecific antibody treatments are being studied for use in patients with multiple myeloma. There are several FDA-approved bispecific treatments, while trispecific therapies remain in the clinical trial phase.
Both bispecific and trispecific antibodies are designed to bind to multiple targets, helping to bridge cancer cells and T-cells, immune cells that play a critical role in destroying cancer. Trispecific antibodies may further enhance this effect by providing an additional T-cell costimulatory signal, potentially increasing target specificity. Another potential benefit of trispecifics is decreased dosing frequency. While bispecific therapies are often administered weekly at the start of treatment, trispecific therapies may be given as infrequently as once every four weeks.
NWMS is part of the Exigent Research Network, a national network focused on advancing innovative therapies, including bispecifics, trispecifics, and CAR-T cell therapy. The network has developed a first-of-its-kind outpatient community oncology model. As part of this network, the NWMS team collaborated with leading sites across the country that have successfully implemented these programs in community settings. Their expertise was instrumental in the development of our program.
Clinical trials enable our providers to evaluate how emerging therapies may benefit broader patient populations. Patients who participate in these studies contribute essential data that helps shape the future of cancer care, and NWMS is proud to offer this opportunity to eligible patients.
Dr. Blau, President of Northwest Medical Specialties, and a hematologist/oncologist, expressed enthusiasm about the first patient enrollment in the trispecific study:
“Bringing trispecific therapies to our patients represents a major advancement in precision immunotherapy. We are excited to expand access to these promising new treatments close to home and to be part of advancing this important research. We will also be participating in the new CAR-T cell therapies this year, with some already on the horizon.”
Patients and referring physicians are encouraged to contact Northwest Medical Specialties to learn more about the trispecifics program and discuss potential treatment options. The organization is dedicated to fostering open communication and collaboration to ensure the best possible outcomes for patients.
Follow the JNJ-79635322 Study here!
Sources: